Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26695770 | 0.91 | ALDH1A1 (0.36) | ALDH1A1LMNASLC15A2PAOXACHE | |
| SCHEMBL4453065 | 0.84 | — | — | |
| SCHEMBL7189063 | 0.82 | DGKA (0.55) | ALDH1A1TSHRDGKA | |
| SCHEMBL21057919 | 0.82 | ALDH1A1 (0.45) | ALDH1A1LMNASLC15A2PAOXACHE | |
| SCHEMBL305496 | 0.82 | ALDH1A1 (0.61) | ALDH1A1LMNASLC15A2PAOXACHE | |
| SCHEMBL9543151 | 0.81 | TSHR (0.39) | ALDH1A1TSHRHCAR2ATMNAAA | |
| SCHEMBL26695997 | 0.79 | LMNA (0.48) | ALDH1A1LMNASLC15A2TSHR | |
| SCHEMBL7606415 | 0.79 | LMNA (0.53) | ALDH1A1LMNATSHR | |
| SCHEMBL17180617 | 0.78 | LMNA (0.46) | ALDH1A1LMNASLC15A2PAOXACHE | |
| SCHEMBL16020394 | 0.78 | ADRA2A (0.48) | ALDH1A1LMNASLC15A2PAOXACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521368-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| EP-4011875-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3710438-B1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11008300-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112521368-A | Triazole N-linked carbamoylcyclohexanoic acids as LPA antagonists | 百时美施贵宝公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-112189010-A | Triazole N-linked carbamoylcyclohexanoic acids as LPA antagonists | 百时美施贵宝公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3710438-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
| EP-0003624-B1 | PROCESS FOR THE PREPARATION OF THE METHYL ESTER OF 4-OXOPENTANE-1-CARBOXYLIC ACID | STAMICARBON B.V. (NL) | 1982-07-28 | — | — | EP | disclosed |
| EP-0003624-A1 | Process for the preparation of the methyl ester of 4-oxopentane-1-carboxylic acid | STAMICARBON B.V. (NL) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ALDH1A1 3478/4885LMNA 1652/4885SLC15A2 2142/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | ALDH1A1 3478/4885LMNA 1652/4885SLC15A2 2142/4885 |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | ALDH1A1 3478/4885LMNA 1652/4885SLC15A2 2142/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | ALDH1A1 3478/4885LMNA 1652/4885SLC15A2 2142/4885 |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | LPAR3, LPAR1, LPAR2 | ALDH1A1 3478/4885LMNA 1652/4885SLC15A2 2142/4885 |
| US-11008300-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | ALDH1A1 3478/4885LMNA 1652/4885SLC15A2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.